期刊文献+

非糜烂性胃食管反流病患者不同治疗方案评价 被引量:10

Evaluation of Different Treatment Protocols of NERD
原文传递
导出
摘要 目的比较以抑酸剂为基础的不同联合用药方案治疗非糜烂性胃食管反流病(NERD)的效果,为临床用药提供指导。方法将53例NERD患者随机分为4组,分别给予抑酸剂(A组)、抑酸剂+利胆药(B组)、抑酸剂+促动力药(C组)、抑酸剂+利胆药+促动力药(D组)等4种方案治疗8周,并记录各组患者治疗前、治疗后第4周、第8周症状评分。然后比较各组治疗前后症状评分的差异以及组间治疗效果的差异。结果 4组患者治疗后第4周、第8周症状评分均降低,差异有统计学意义(P<0.05)。治疗后,D组患者症状评分降低最明显,显著低于其他3组,差异有统计学意义(P<0.05)。结论在NERD的治疗中,以抑酸剂为基础的联合用药效果要优于单用抑酸剂者,而抑酸剂联合促动力药及利胆剂治疗NERD可使治疗效果达到最佳。 Objective To compare the clinical results of different treatment protocols basing on acid inhibitor of non- crosive gastroesophageal reflux disease (NERD) , and direct the clinical works. Methods 53 patients with NERD were divided into 4 groups, and 4 treatment protocols. Acid inhibitor, acid inhibitor + cholagogue, acid inhibitor + dynamics- promoting medi- cine, and acid inhibitor + cholaegogue + dynamics- promoting medicine,were given to group A, B, C and D respectively, and the treatment course was 8 weeks. The symptom score of each group was record at such point as pre-treatment,4 weeks after treat- rrlent, and 8 weeks after treatment. Compared the difference of the symptom scores of each group to find the difference between e^ch treatment protocol. Results The symptom scores of 4 weeks and 8 weeks after treatment of 4 groups declined obviously, compared with those of pre- treatment, the difference was significant ( P 〈 0.05 ). And the post- treatment symptom score of D group was lower than those of other 3 groups, the difference was significant (P 〈 0.05 ). Conclusion In treatment of NERD, a treatment protocol basing on acid inhibitor can get a better result than that of single acid inhibitor, and acid inhibitor + cholae- gogue + dynamics promoting medicine can get the best result in the 4 protocols we observed.
出处 《临床消化病杂志》 2012年第3期156-158,共3页 Chinese Journal of Clinical Gastroenterology
关键词 非糜烂性胃食管反流病 治疗 联合用药 比较研究 non- erosive gastroesophageal reflux disease Treatment Drug combination Comparation
  • 相关文献

参考文献11

  • 1CALABRESE C, BORTOLOTTI M, FABBRI A, et al. ReversibilityOf- GERDuhrastructural alterations and relief of symp toms after omep razole treatment[J]. Am J. Castronentero1,2005 ,100 :537.
  • 2KAHRILAS PJ, MINER P, JOHANSON J, et al. Efficacy of rabep razole in the treatment of symptomatic gastroesophageal reflux disease [ J ]. Dig. Dis Sci, 2005,50 ( 11 ) : 2009.
  • 3BATE CM, GRIFFIN SM, KEELING PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis[ J]. Al- iment Pharmacol Ther,1996,10(4) :547.
  • 4Lind T, HAVELUND T, CARLSSON R, et al. Heartburn without oe- sophagitis:efficaey of omeprazole therapy and features determining therapeutic response [ J ]. Seand J Gastroenterol, 1997,32 ( 10 ) :974.
  • 5MINER P Jr, ORR W, FILIPPONE J, et al. Rabeprazole in noneroslve gastroesophageal reflux disease:a randomized placebo-controlled trial [ J ]. Am J Gastroenterol,2002,97 (6) : 1332.
  • 6戴自英.实用内科学[M]第9版[M].北京:人民卫生出版社,1993.1303.
  • 7刘锡能 杨彤翰.国嘉胆维他片的临床疗效观察[A]..国嘉胆维他片临床资料与基础研究汇编[C].成都国嘉生物制药股份有限公司出版,2002.20.
  • 8QUIGLEY EM. New developmntsinthe pathophysiology of gastro-oeso- phageal reflux disease(GERD) :Implications for patient management [ J]. Aliment Pharmacol Ther ,2003,17 ( Suppl 2) :43.
  • 9TACK J. Recent developments in the pathophyslology and therapy of gastroesophageal reflux disease and nonereslve reflux disease [ J ]. Curt Opin Gastreenterol;2005,21:454.
  • 10De CAESTECKER J. Prekineties and reuux: a promise unfulfilled [ J ]. Eur Gastroenterol Hepatol,2002,14:5.

二级参考文献3

共引文献34

同被引文献110

  • 1张珊珊,王智峰,刘玉兰.非糜烂性胃食管反流病发病机制的研究[J].中国实用内科杂志,2005,25(6):525-527. 被引量:16
  • 2徐海荣,卜平,袁洋,陈洁.胃食管反流病中西医结合治疗及疗效标准研究——附116例临床观察[J].中国中西医结合杂志,2007,27(3):204-207. 被引量:16
  • 3Vakil N, van Zanten SV, Kahrilas P, et 81. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence - based consensus [ J ]. Am J Gastroenterol, 2006, 101 ( 8 ) : 1900 - 1920.
  • 4Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease [ J ]. Clin Gastroenterol Hepatol,2007,5 ( 1 ) :4 - 16.
  • 5E1 - Serag HB, Satia JA, Rabeneek L. Dietary intake and the risk of gastrooesophageal reflux disease: a cross sectional study in volunteers [J]. Gut,2005,54( 1 ) : 11 - 17.
  • 6Everhart JE. Gastroesophageal reflux disease [ M ]. Washington: The Burden of Digestive Disease in the United States,2008:68 -72.
  • 7Ndraha S. Combination of PPI with a prokinetie drug in gastrcesopha- geal reflux disease [ J ]. Acta Med Indones,2011,43 ( 4 ) : 233 - 236.
  • 8Ament PW, Dicola DB, James ME. Reducing adverse effects of pro- ton pump inhibitors[ J ]. Am Faro Physician ,2012,86 ( 1 ) :66 - 70.
  • 9Metz DC, Vakily M, Dixit T, et al. Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release pmtonpump inhibitor therapy [ J ]. Ali- ment Pharmacol Ther,2009,29 : 928 -937.
  • 10Fass R. Pump Inhibitor failure - what are the therapeutic options[ J]. Am J Gastroentero1,2009,104( Suppl 2) :S33 - S38.

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部